Pre-made Rilotumumab benchmark antibody ( Whole mAb, anti-HGF therapeutic antibody, Anti-DFNB39/F-TCF/HPTA/SF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Rilotumumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-483-1mg	1mg	3090
GMP-Bios-ab-483-10mg	10mg	Inquiry
GMP-Bios-ab-483-100mg	100mg	Inquiry
GMP-Bios-ab-483-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rilotumumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody
INN Name	Rilotumumab
Target	HGF
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Amgen;Astellas Pharma
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours
Development Tech	Abgenix XenoMouse